Larimar Therapeutics Net Income
| LRMR Stock | USD 3.48 0.11 3.26% |
As of the 10th of February, Larimar Therapeutics secures the Mean Deviation of 3.57, risk adjusted performance of (0.01), and Standard Deviation of 4.79. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Larimar Therapeutics, as well as the relationship between them. Please verify Larimar Therapeutics market risk adjusted performance and treynor ratio to decide if Larimar Therapeutics is priced some-what accurately, providing market reflects its recent price of 3.48 per share. Given that Larimar Therapeutics has information ratio of (0.04), we recommend you to check Larimar Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.
Larimar Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Larimar Therapeutics' valuation are provided below:There are over one hundred nineteen available fundamental ratios for Larimar Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to check Larimar Therapeutics' last-minute fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 02/10/2026, Market Cap is likely to drop to about 254.1 M. In addition to that, Enterprise Value is likely to drop to about 218.6 M This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -72.5 M | -68.9 M | |
| Net Loss | -40.7 M | -42.7 M | |
| Net Loss | -72.5 M | -68.9 M | |
| Net Loss | (1.18) | (1.24) | |
| Net Income Per E B T | 1.15 | 1.09 |
Larimar | Net Income | Build AI portfolio with Larimar Stock |
Evaluating Larimar Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Larimar Therapeutics's fundamental strength.
Latest Larimar Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Larimar Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Larimar Therapeutics financial statement analysis. It represents the amount of money remaining after all of Larimar Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Larimar Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Larimar Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (80.6 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Larimar Net Income Regression Statistics
| Arithmetic Mean | (43,842,178) | |
| Coefficient Of Variation | (53.00) | |
| Mean Deviation | 19,670,188 | |
| Median | (42,327,000) | |
| Standard Deviation | 23,235,845 | |
| Sample Variance | 539.9T | |
| Range | 67.4M | |
| R-Value | (0.66) | |
| Mean Square Error | 326.6T | |
| R-Squared | 0.43 | |
| Significance | 0 | |
| Slope | (3,027,612) | |
| Total Sum of Squares | 8638.5T |
Larimar Net Income History
Other Fundumenentals of Larimar Therapeutics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Larimar Therapeutics Net Income component correlations
Larimar Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Larimar Therapeutics is extremely important. It helps to project a fair market value of Larimar Stock properly, considering its historical fundamentals such as Net Income. Since Larimar Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Larimar Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Larimar Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Larimar have expansion opportunities? Factors like these will boost the valuation of Larimar Therapeutics. Expected growth trajectory for Larimar significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Larimar Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Larimar Therapeutics's market price often diverges from its book value, the accounting figure shown on Larimar's balance sheet. Smart investors calculate Larimar Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Larimar Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Larimar Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Larimar Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Larimar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Larimar Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Larimar Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Larimar Therapeutics.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Larimar Therapeutics on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Larimar Therapeutics or generate 0.0% return on investment in Larimar Therapeutics over 90 days. Larimar Therapeutics is related to or competes with EnGene Holdings, Annexon, DBV Technologies, Amarin PLC, Altimmune, Kyverna Therapeutics, and Frequency Therapeutics. Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases u... More
Larimar Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Larimar Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Larimar Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 20.14 | |||
| Value At Risk | (7.49) | |||
| Potential Upside | 7.76 |
Larimar Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Larimar Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Larimar Therapeutics' standard deviation. In reality, there are many statistical measures that can use Larimar Therapeutics historical prices to predict the future Larimar Therapeutics' volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.14) | |||
| Total Risk Alpha | (0.64) | |||
| Treynor Ratio | (0.33) |
Larimar Therapeutics February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.32) | |||
| Mean Deviation | 3.57 | |||
| Coefficient Of Variation | (4,852) | |||
| Standard Deviation | 4.79 | |||
| Variance | 22.93 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.14) | |||
| Total Risk Alpha | (0.64) | |||
| Treynor Ratio | (0.33) | |||
| Maximum Drawdown | 20.14 | |||
| Value At Risk | (7.49) | |||
| Potential Upside | 7.76 | |||
| Skewness | (0.30) | |||
| Kurtosis | 1.25 |
Larimar Therapeutics Backtested Returns
Currently, Larimar Therapeutics is moderately volatile. Larimar Therapeutics has Sharpe Ratio of 0.0335, which conveys that the firm had a 0.0335 % return per unit of risk over the last 3 months. We have found twenty-three technical indicators for Larimar Therapeutics, which you can use to evaluate the volatility of the firm. Please verify Larimar Therapeutics' Risk Adjusted Performance of (0.01), standard deviation of 4.79, and Mean Deviation of 3.57 to check out if the risk estimate we provide is consistent with the expected return of 0.15%. Larimar Therapeutics has a performance score of 2 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.33, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Larimar Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Larimar Therapeutics is expected to be smaller as well. Larimar Therapeutics right now secures a risk of 4.36%. Please verify Larimar Therapeutics treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Larimar Therapeutics will be following its current price movements.
Auto-correlation | 0.16 |
Very weak predictability
Larimar Therapeutics has very weak predictability. Overlapping area represents the amount of predictability between Larimar Therapeutics time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Larimar Therapeutics price movement. The serial correlation of 0.16 indicates that over 16.0% of current Larimar Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.16 | |
| Spearman Rank Test | 0.13 | |
| Residual Average | 0.0 | |
| Price Variance | 0.04 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Larimar Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Larimar Therapeutics reported net income of (80.6 Million). This is 123.62% lower than that of the Biotechnology sector and 215.07% lower than that of the Health Care industry. The net income for all United States stocks is 114.12% higher than that of the company.
Larimar Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Larimar Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Larimar Therapeutics could also be used in its relative valuation, which is a method of valuing Larimar Therapeutics by comparing valuation metrics of similar companies.Larimar Therapeutics is currently under evaluation in net income category among its peers.
Larimar Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Larimar Therapeutics from analyzing Larimar Therapeutics' financial statements. These drivers represent accounts that assess Larimar Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Larimar Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 185.2M | 106.4M | 199.8M | 237.1M | 272.6M | 254.1M | |
| Enterprise Value | 121.1M | 85.0M | 178.5M | 209.0M | 240.3M | 218.6M |
Larimar Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Larimar Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Larimar Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Larimar Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Larimar Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Larimar Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Larimar Therapeutics' value.| Shares | Two Sigma Investments Llc | 2025-06-30 | 903.6 K | State Street Corp | 2025-06-30 | 859 K | Mangrove Partners | 2025-06-30 | 770.2 K | Caption Management, Llc | 2025-06-30 | 689.3 K | Woodline Partners Lp | 2025-06-30 | 622.7 K | Verition Fund Managegment, Llc | 2025-06-30 | 567.7 K | Renaissance Technologies Corp | 2025-06-30 | 561.7 K | Driehaus Capital Management Llc | 2025-06-30 | 535.5 K | Aqr Capital Management Llc | 2025-06-30 | 428.5 K | Deerfield Management Co | 2025-06-30 | 21.2 M | Ra Capital Management, Llc | 2025-06-30 | 6 M |
Larimar Fundamentals
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.43 | ||||
| Current Valuation | 108.1 M | ||||
| Shares Outstanding | 83.09 M | ||||
| Shares Owned By Insiders | 1.10 % | ||||
| Shares Owned By Institutions | 98.90 % | ||||
| Number Of Shares Shorted | 8.59 M | ||||
| Price To Book | 2.01 X | ||||
| EBITDA | (90.57 M) | ||||
| Net Income | (80.6 M) | ||||
| Cash And Equivalents | 54.92 M | ||||
| Cash Per Share | 3.10 X | ||||
| Total Debt | 5.12 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 7.35 X | ||||
| Book Value Per Share | 1.62 X | ||||
| Cash Flow From Operations | (70.76 M) | ||||
| Short Ratio | 7.42 X | ||||
| Earnings Per Share | (1.96) X | ||||
| Target Price | 14.67 | ||||
| Number Of Employees | 65 | ||||
| Beta | 1.0 | ||||
| Market Capitalization | 288.44 M | ||||
| Total Asset | 200.22 M | ||||
| Retained Earnings | (269.16 M) | ||||
| Working Capital | 170.95 M | ||||
| Net Asset | 200.22 M |
About Larimar Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Larimar Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Larimar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Larimar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Larimar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Larimar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Larimar Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Larimar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Larimar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Larimar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Larimar Therapeutics to buy it.
The correlation of Larimar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Larimar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Larimar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Larimar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Larimar Stock Analysis
When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.